PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

Bibliographic Details
Main Authors:	Cooper, C, Liggins, A, Ait-Tahar, K, Roncador, G, Banham, A, Pulford, K
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
by: Campbell, A, et al.
Published: (2010)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2009)

PASD1 is a potential multiple myeloma-associated antigen.
by: Sahota, S, et al.
Published: (2006)

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
by: Joseph-Pietras, D, et al.
Published: (2010)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
by: Ait-Tahar, K, et al.
Published: (2009)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2011)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
by: Kamel Ait-Tahar, et al.
Published: (2011-01-01)

A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
by: Liggins, A, et al.
Published: (2004)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
by: Liggins, A, et al.
Published: (2004)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
by: Cooper, C, et al.
Published: (2011)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
by: Liggins, A, et al.
Published: (2010)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
by: Liggins, A, et al.
Published: (2010)

Erratum: Serologic detection of diffuse large B-cell lymphoma-associated antigens (International Journal of Cancer (2004) 110 (563-569))
by: Liggins, A, et al.
Published: (2004)

Identification of lymphoma-associated antigens using SEREX.
by: Liggins, A, et al.
Published: (2005)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
by: Christopher D O Cooper, et al.
Published: (2011-01-01)

Immunochemical studies of antigenic lymphoma-associated proteins.
by: Pulford, K, et al.
Published: (2002)

CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY
by: D. I. Vodolazhsky, et al.
Published: (2017-06-01)

Cancer testis antigen and immunotherapy
by: Krishnadas DK, et al.
Published: (2013-04-01)

MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
by: Liggins, A, et al.
Published: (2007)

Sp17 protein expression and major histocompatibility class I and II epitope presentation in diffuse large B cell lymphoma patients
by: Ait-Tahar, K, et al.
Published: (2017)

Cancer Testis Antigens and Immunotherapy: A new Dawn
by: Zhang Bingcan
Published: (2021-01-01)

Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
by: Lawrie, C, et al.
Published: (2006)

Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling
by: Wong, K, et al.
Published: (2008)

Identification of Huntingtin interacting protein 1 related (HIP1R) as a novel lymphoma autoantigen using antigen array profiling
by: Wong, K, et al.
Published: (2009)

Unveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma
by: Shenghua Zhuo, et al.
Published: (2024-10-01)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
by: Barrans, S, et al.
Published: (2004)

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
by: Huihan Ai, et al.
Published: (2023-06-01)

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects
by: Xiao Wei, et al.
Published: (2019-05-01)

Expression of cancer testis antigens in patients with Hodgkin's lymphoma and their clinical correlation
by: L.M. Hodgson Reyes, et al.
Published: (2018-01-01)

RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis.
by: Patel, S, et al.
Published: (2012)

RNASET2 - An autoantigen in anaplastic large cell lymphoma identified by protein array analysis
by: Patel, S, et al.
Published: (2012)

Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
by: Brown, P, et al.
Published: (2008)

Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse—a case report
by: M. C. Suresh Babu, et al.
Published: (2020-05-01)

Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.
by: Patel, S, et al.
Published: (2014)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
by: Madiha Iqbal, et al.
Published: (2022-01-01)

The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy
by: Lina Lin, et al.
Published: (2024-06-01)

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
by: Kamel Ait-Tahar, et al.
Published: (2017-01-01)

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
by: Lawrie, C, et al.
Published: (2008)

LYMPHOMA PADA TESTIS
by: Dian Yuliartha Lestari, et al.
Published: (2018-09-01)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
by: Griffiths, R, et al.
Published: (2010)